title: Effects of prostaglandin E1 on reperfusion injury patients: A meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  Prostaglandin E1 (PGE1) is widely used as a pretreatment for myocardial reperfusion injury in animal experiments. However, the cardioprotective effects of PGE1 in patients have not been established. We performed a meta-analysis to investigate whether PGE1 is cardioprotective, based on the reduction of correlative reperfusion injury events (CRIE), major adverse cardiac events (MACE), and biomarker release in patients with ischemia reperfusion injury.
  
  
  METHODS
  The Medline, EMBASE, and Cochrane databases were searched for randomized clinical trials confirming the effects of PGE1. Two investigators independently selected suitable trials, assessed trial quality, and extracted data.
  
  
  RESULTS
  Six studies in patients undergoing percutaneous coronary intervention (4 studies) and cardiac surgery (2 studies), comprising a total of 445 patients, were included in this review. The results showed that PGE1 reduced the incidence of CRIE (relative ratio 0.4 [95% confidence interval 0.43, 0.95]), the incidence of MACE (0.35 [0.17, 0.70]), and the level of troponin T (standardized mean difference 20.28 [20.47, 20.09]), creatine kinase-MB (-1.74 [-3.21, - 0.27]), interleukin-6 (-1.37 [-2.69, - 0.04]), and interleukin-8 (-2.05 [-2.75, - 1.34]).
  
  
  CONCLUSIONS
  PGE1 may have beneficial effects on myocardial reperfusion injury in the clinic.
authors.affiliation: Zhejiang Chinese Medical University Hnagzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang, China.
authors.forename: Houyong
authors.initials: H
authors.lastname: Zhu
authors.forename: Xiaoqun
authors.initials: X
authors.lastname: Xu
authors.forename: Yu
authors.initials: Y
authors.lastname: Ding
authors.forename: Liang
authors.initials: L
authors.lastname: Zhou
authors.forename: Jinyu
authors.initials: J
authors.lastname: Huang
mesh_terms: D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D006348:Cardiac Surgical Procedures / Q000009:adverse effects* / Q000379:methods; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D052279:Creatine Kinase, MB Form / Q000097:blood; D005260:Female; D006801:Humans; D015994:Incidence; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects* / Q000379:methods; D011184:Postoperative Period; D016032:Randomized Controlled Trials as Topic; D020107:Troponin T / Q000097:blood
chemical_list: D015415:Biomarkers; C508606:CXCL8 protein, human; D002316:Cardiotonic Agents; C508600:IL6 protein, human; D015850:Interleukin-6; D016209:Interleukin-8; D020107:Troponin T; D052279:Creatine Kinase, MB Form; D000527:Alprostadil